**IN THE CLAIMS:**

Claims 1-38 **(cancelled)**.

Claim 39 **(currently amended)**: A compound of the formula II:

(II) 

wherein:

ring C is a 9 or 10-membered heteroaromatic ~~an 8, 9, 10, 12 or 13-membered~~ bicyclic ~~or tricyclic~~ moiety ~~which moiety may be saturated or unsaturated, which may be aromatic or non-aromatic, and~~ which contains 1-3 heteroatoms selected independently from O, N and S;

Zb is -O- or -S-;

n is an integer from 0 to 5;

$R^2$ represents hydroxy, halogeno, cyano, nitro, trifluoromethyl, $C_{1-3}$alkyl, $C_{1-3}$alkoxy, $C_{1-3}$alkylsulphanyl, $-NR^3R^4$ (wherein $R^3$ and $R^4$, which may be the same or different, each represents hydrogen or $C_{1-3}$alkyl),

or $R^2$ represents a group $R^5X^1$-, wherein $X^1$ represents a direct bond, -O-, $-CH_2$-, -OC(O)-, -C(O)-, -S-, -SO-, $-SO_2$-, $-NR^6C(O)$-, $-C(O)NR^7$-, $-SO_2NR^8$-, $-NR^9SO_2$- or $-NR^{10}$- (wherein $R^6$, $R^7$, $R^8$, $R^9$ and $R^{10}$ each independently represents hydrogen, $C_{1-3}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl), and $R^5$ is selected from one of the following twenty-two groups:

1) hydrogen, oxiranyl$C_{1-4}$alkyl or $C_{1-5}$alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, chloro, bromo and amino;

2) $C_{1-5}alkylX^2C(O)R^{11}$ (wherein $X^2$ represents -O- or $-NR^{12}$- (in which $R^{12}$ represents hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$) and $R^{11}$ represents $C_{1-3}alkyl$, $-NR^{13}R^{14}$ or $-OR^{15}$ (wherein $R^{13}$, $R^{14}$ and $R^{15}$ which may be the same or different each represents hydrogen, $C_{1-5}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$));

3) $C_{1-5}alkylX^3R^{16}$ (wherein $X^3$ represents -O-, -S-, -SO-, $-SO_2$-, -OC(O)-, $-NR^{17}C(O)$-, $-C(O)NR^{18}$-, $-SO_2NR^{19}$-, $-NR^{20}SO_2$- or $-NR^{21}$- (wherein $R^{17}$, $R^{18}$, $R^{19}$, $R^{20}$ and $R^{21}$ each independently represents hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$) and $R^{16}$ represents hydrogen, $C_{1-3}alkyl$, cyclopentyl, cyclohexyl or a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which $C_{1-3}alkyl$ group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and $C_{1-4}alkoxy$ and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, $C_{1-4}cyanoalkyl$, $C_{1-4}alkyl$, $C_{1-4}hydroxyalkyl$, $C_{1-4}alkoxy$, $C_{1-4}alkoxyC_{1-4}alkyl$, $C_{1-4}alkylsulphonylC_{1-4}alkyl$, $C_{1-4}alkoxycarbonyl$, $C_{1-4}aminoalkyl$, $C_{1-4}alkylamino$, $di(C_{1-4}alkyl)amino$, $C_{1-4}alkylaminoC_{1-4}alkyl$, $di(C_{1-4}alkyl)aminoC_{1-4}alkyl$, $C_{1-4}alkylaminoC_{1-4}alkoxy$, $di(C_{1-4}alkyl)aminoC_{1-4}alkoxy$ and a group $-(-O-)_f(C_{1-4}alkyl)_gringD$ (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from $C_{1-4}alkyl$));

4) $C_{1-5}alkylX^4C_{1-5}alkylX^5R^{22}$ (wherein $X^4$ and $X^5$ which may be the same or different are each -O-, -S-, -SO-, $-SO_2$-, $-NR^{23}C(O)$-, $-C(O)NR^{24}$-, $-SO_2NR^{25}$-, $-NR^{26}SO_2$- or $-NR^{27}$- (wherein $R^{23}$, $R^{24}$, $R^{25}$, $R^{26}$ and $R^{27}$ each independently represents hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$) and $R^{22}$ represents hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$);

5) $R^{28}$ (wherein $R^{28}$ is a 4-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, $C_{1-4}cyanoalkyl$, $C_{1-4}alkyl$, $C_{1-4}hydroxyalkyl$, $C_{1-4}alkoxy$, $C_{1-4}alkoxyC_{1-4}alkyl$, $C_{1-4}alkylsulphonylC_{1-4}alkyl$, $C_{1-4}alkoxycarbonyl$, $C_{1-4}aminoalkyl$, $C_{1-4}alkylamino$, $di(C_{1-4}alkyl)amino$, $C_{1-4}alkylaminoC_{1-4}alkyl$, $di(C_{1-4}alkyl)aminoC_{1-4}alkyl$,

$C_{1-4}$alkylamino$C_{1-4}$alkoxy, di($C_{1-4}$alkyl)amino$C_{1-4}$alkoxy and a group -(-O-)$_f$($C_{1-4}$alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from $C_{1-4}$alkyl));

6) $C_{1-5}$alkyl$R^{28}$ (wherein $R^{28}$ is as defined herein);

7) $C_{2-5}$alkenyl$R^{28}$ (wherein $R^{28}$ is as defined herein);

8) $C_{2-5}$alkynyl$R^{28}$ (wherein $R^{28}$ is as defined herein);

9) $R^{29}$ (wherein $R^{29}$ represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from hydroxy, halogeno, amino, $C_{1-4}$alkyl, $C_{1-4}$alkoxy, $C_{1-4}$hydroxyalkyl, $C_{1-4}$aminoalkyl, $C_{1-4}$alkylamino, $C_{1-4}$hydroxyalkoxy, carboxy, trifluoromethyl, cyano, -C(O)N$R^{30}R^{31}$, -N$R^{32}$C(O)$R^{33}$ (wherein $R^{30}$, $R^{31}$, $R^{32}$ and $R^{33}$, which may be the same or different, each represents hydrogen, $C_{1-4}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl) and a group -(-O-)$_f$($C_{1-4}$alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from $C_{1-4}$alkyl));

10) $C_{1-5}$alkyl$R^{29}$ (wherein $R^{29}$ is as defined herein);

11) $C_{2-5}$alkenyl$R^{29}$ (wherein $R^{29}$ is as defined herein);

12) $C_{2-5}$alkynyl$R^{29}$ (wherein $R^{29}$ is as defined herein);

13) $C_{1-5}$alkyl$X^6R^{29}$ (wherein $X^6$ represents -O-, -S-, -SO-, -$SO_2$-, -N$R^{34}$C(O)-, -C(O)N$R^{35}$-, -$SO_2$N$R^{36}$-, -N$R^{37}SO_2$- or -N$R^{38}$- (wherein $R^{34}$, $R^{35}$, $R^{36}$, $R^{37}$ and $R^{38}$ each independently represents hydrogen, $C_{1-3}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl) and $R^{29}$ is as defined herein);

14) $C_{2-5}$alkenyl$X^7R^{29}$ (wherein $X^7$ represents -O-, -S-, -SO-, -$SO_2$-, -N$R^{39}$C(O)-, -C(O)N$R^{40}$-, -$SO_2$N$R^{41}$-, -N$R^{42}SO_2$- or -N$R^{43}$- (wherein $R^{39}$, $R^{40}$, $R^{41}$, $R^{42}$ and $R^{43}$ each independently represents hydrogen, $C_{1-3}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl) and $R^{29}$ is as defined herein);

15) $C_{2-5}$alkynyl$X^8R^{29}$ (wherein $X^8$ represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{44}C(O)-$, $-C(O)NR^{45}-$, $-SO_2NR^{46}-$, $-NR^{47}SO_2-$ or $-NR^{48}-$ (wherein $R^{44}$, $R^{45}$, $R^{46}$, $R^{47}$ and $R^{48}$ each independently represents hydrogen, $C_{1-3}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl) and $R^{29}$ is as defined herein);

16) $C_{1-4}$alkyl$X^9C_{1-4}$alkyl$R^{29}$ (wherein $X^9$ represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{49}C(O)-$, $-C(O)NR^{50}-$, $-SO_2NR^{51}-$, $-NR^{52}SO_2-$ or $-NR^{53}-$ (wherein $R^{49}$, $R^{50}$, $R^{51}$, $R^{52}$ and $R^{53}$ each independently represents hydrogen, $C_{1-3}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl) and $R^{29}$ is as defined herein);

17) $C_{1-4}$alkyl$X^9C_{1-4}$alkyl$R^{28}$ (wherein $X^9$ and $R^{28}$ are as defined herein);

18) $C_{2-5}$alkenyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, $C_{1-4}$alkylamino, N,N-di($C_{1-4}$alkyl)amino, aminosulphonyl, N-$C_{1-4}$alkylaminosulphonyl and N,N-di($C_{1-4}$alkyl)aminosulphonyl;

19) $C_{2-5}$alkynyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, $C_{1-4}$alkylamino, N,N-di($C_{1-4}$alkyl)amino, aminosulphonyl, N-$C_{1-4}$alkylaminosulphonyl and N,N-di($C_{1-4}$alkyl)aminosulphonyl;

20) $C_{2-5}$alkenyl$X^9C_{1-4}$alkyl$R^{28}$ (wherein $X^9$ and $R^{28}$ are as defined herein);

21) $C_{2-5}$alkynyl$X^9C_{1-4}$alkyl$R^{28}$ (wherein $X^9$ and $R^{28}$ are as defined herein); and

22) $C_{1-4}$alkyl$R^{54}(C_{1-4}\text{alkyl})_q(X^9)_rR^{55}$ (wherein $X^9$ is as defined herein, q is 0 or 1, r is 0 or 1, and $R^{54}$ and $R^{55}$ are each independently selected from hydrogen, $C_{1-3}$alkyl, cyclopentyl, cyclohexyl and a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which $C_{1-3}$alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and $C_{1-4}$alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, $C_{1-4}$cyanoalkyl, $C_{1-4}$alkyl, $C_{1-4}$hydroxyalkyl, $C_{1-4}$alkoxy, $C_{1-4}$alkoxy$C_{1-4}$alkyl, $C_{1-4}$alkylsulphonyl$C_{1-4}$alkyl, $C_{1-4}$alkoxycarbonyl, $C_{1-4}$aminoalkyl, $C_{1-4}$alkylamino, di($C_{1-4}$alkyl)amino, $C_{1-4}$alkylamino$C_{1-4}$alkyl, di($C_{1-4}$alkyl)amino$C_{1-4}$alkyl, $C_{1-4}$alkylamino$C_{1-4}$alkoxy, di($C_{1-4}$alkyl)amino$C_{1-4}$alkoxy and a group $-(-O-)_f(C_{1-4}\text{alkyl})_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S

and N, which cyclic group may bear one or more substituents selected from $C_{1-4}$alkyl), with the proviso that $R^{54}$ cannot be hydrogen);

and additionally wherein any $C_{1-5}$alkyl, $C_{2-5}$alkenyl or $C_{2-5}$alkynyl group in $R^5X^1$- may bear one or more substituents selected from hydroxy, halogeno and amino;

$R^1$ represents hydrogen, oxo, halogeno, hydroxy, $C_{1-4}$alkoxy, $C_{1-4}$alkyl, $C_{1-4}$alkoxymethyl, $C_{1-4}$alkanoyl, $C_{1-4}$haloalkyl, cyano, amino, $C_{2-5}$alkenyl, $C_{2-5}$alkynyl, $C_{1-3}$alkanoyloxy, nitro, $C_{1-4}$alkanoylamino, $C_{1-4}$alkoxycarbonyl, $C_{1-4}$alkylsulphanyl, $C_{1-4}$alkylsulphinyl, $C_{1-4}$alkylsulphonyl, carbamoyl, N-$C_{1-4}$alkylcarbamoyl, N,N-di($C_{1-4}$alkyl)carbamoyl, aminosulphonyl, N-$C_{1-4}$alkylaminosulphonyl, N,N-di($C_{1-4}$alkyl)aminosulphonyl, N-($C_{1-4}$alkylsulphonyl)amino, N-($C_{1-4}$alkylsulphonyl)-N-($C_{1-4}$alkyl)amino, N,N-di($C_{1-4}$alkylsulphonyl)amino, a $C_{3-7}$alkylene chain joined to two ring C carbon atoms, $C_{1-4}$alkanoylamino$C_{1-4}$alkyl, carboxy,

or $R^1$ represents a group $R^{56}X^{10}$, wherein $X^{10}$ represents a direct bond, -O-, -$CH_2$-, -OC(O)-, -C(O)-, -S-, -SO-, -$SO_2$-, -$NR^{57}$C(O)-, -C(O)$NR^{58}$-, -$SO_2NR^{59}$-, -$NR^{60}SO_2$- or -$NR^{61}$- (wherein $R^{57}$, $R^{58}$, $R^{59}$, $R^{60}$ and $R^{61}$ each independently represents hydrogen, $C_{1-3}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl), and $R^{56}$ is selected from one of the following twenty-two groups:

1) hydrogen, oxiranyl$C_{1-4}$alkyl or $C_{1-5}$alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, chloro, bromo and amino;

2) $C_{1-5}$alkyl$X^{11}$C(O)$R^{62}$ (wherein $X^{11}$ represents -O- or -$NR^{63}$- (in which $R^{63}$ represents hydrogen, $C_{1-3}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl) and $R^{62}$ represents $C_{1-3}$alkyl, -$NR^{64}R^{65}$ or -$OR^{66}$ (wherein $R^{64}$, $R^{65}$ and $R^{66}$ which may be the same or different each represents hydrogen, $C_{1-5}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl));

3) $C_{1-5}$alkyl$X^{12}R^{67}$ (wherein $X^{12}$ represents -O-, -S-, -SO-, -$SO_2$-, -OC(O)-, -$NR^{68}$C(O)-, -C(O)$NR^{69}$-, -$SO_2NR^{70}$-, -$NR^{71}SO_2$- or -$NR^{72}$- (wherein $R^{68}$, $R^{69}$, $R^{70}$, $R^{71}$ and $R^{72}$ each independently represents hydrogen, $C_{1-3}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl) and $R^{67}$ represents hydrogen, $C_{1-3}$alkyl, cyclopentyl, cyclohexyl or a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which $C_{1-3}$alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and

$C_{1-4}$alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, $C_{1-4}$cyanoalkyl, $C_{1-4}$alkyl, $C_{1-4}$hydroxyalkyl, $C_{1-4}$alkoxy, $C_{1-4}$alkoxy$C_{1-4}$alkyl, $C_{1-4}$alkylsulphonyl$C_{1-4}$alkyl, $C_{1-4}$alkoxycarbonyl, $C_{1-4}$aminoalkyl, $C_{1-4}$alkylamino, di($C_{1-4}$alkyl)amino, $C_{1-4}$alkylamino$C_{1-4}$alkyl, di($C_{1-4}$alkyl)amino$C_{1-4}$alkyl, $C_{1-4}$alkylamino$C_{1-4}$alkoxy, di($C_{1-4}$alkyl)amino$C_{1-4}$alkoxy and a group -(-O-)$_f$($C_{1-4}$alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from $C_{1-4}$alkyl));

4) $C_{1-5}$alkyl$X^{13}C_{1-5}$alkyl$X^{14}R^{73}$ (wherein $X^{13}$ and $X^{14}$ which may be the same or different are each -O-, -S-, -SO-, -$SO_2$-, -$NR^{74}C(O)$-, -$C(O)NR^{75}$-, -$SO_2NR^{76}$-, -$NR^{77}SO_2$- or -$NR^{78}$- (wherein $R^{74}$, $R^{75}$, $R^{76}$, $R^{77}$ and $R^{78}$ each independently represents hydrogen, $C_{1-3}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl) and $R^{73}$ represents hydrogen, $C_{1-3}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl);

5) $R^{79}$ (wherein $R^{79}$ is a 4-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, $C_{1-4}$cyanoalkyl, $C_{1-4}$alkyl, $C_{1-4}$hydroxyalkyl, $C_{1-4}$alkoxy, $C_{1-4}$alkoxy$C_{1-4}$alkyl, $C_{1-4}$alkylsulphonyl$C_{1-4}$alkyl, $C_{1-4}$alkoxycarbonyl, $C_{1-4}$aminoalkyl, $C_{1-4}$alkylamino, di($C_{1-4}$alkyl)amino, $C_{1-4}$alkylamino$C_{1-4}$alkyl, di($C_{1-4}$alkyl)amino$C_{1-4}$alkyl, $C_{1-4}$alkylamino$C_{1-4}$alkoxy, di($C_{1-4}$alkyl)amino$C_{1-4}$alkoxy and a group -(-O-)$_f$($C_{1-4}$alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from $C_{1-4}$alkyl));

6) $C_{1-5}$alkyl$R^{79}$ (wherein $R^{79}$ is as defined herein);

7) $C_{2-5}$alkenyl$R^{79}$ (wherein $R^{79}$ is as defined herein);

8) $C_{2-5}$alkynyl$R^{79}$ (wherein $R^{79}$ is as defined herein);

9) $R^{80}$ (wherein $R^{80}$ represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms

selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from hydroxy, halogeno, amino, $C_{1-4}$alkyl, $C_{1-4}$alkoxy, $C_{1-4}$hydroxyalkyl, $C_{1-4}$aminoalkyl, $C_{1-4}$alkylamino, $C_{1-4}$hydroxyalkoxy, carboxy, trifluoromethyl, cyano, $-C(O)NR^{81}R^{82}$, $-NR^{83}C(O)R^{84}$ (wherein $R^{81}$, $R^{82}$, $R^{83}$ and $R^{84}$, which may be the same or different, each represents hydrogen, $C_{1-4}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl) and a group $-(-O-)_f(C_{1-4}alkyl)_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from $C_{1-4}$alkyl));

10) $C_{1-5}$alkyl$R^{80}$ (wherein $R^{80}$ is as defined herein);

11) $C_{2-5}$alkenyl$R^{80}$ (wherein $R^{80}$ is as defined herein);

12) $C_{2-5}$alkynyl$R^{80}$ (wherein $R^{80}$ is as defined herein);

13) $C_{1-5}$alkyl$X^{15}R^{80}$ (wherein $X^{15}$ represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{85}C(O)-$, $-C(O)NR^{86}-$, $-SO_2NR^{87}-$, $-NR^{88}SO_2-$ or $-NR^{89}-$ (wherein $R^{85}$, $R^{86}$, $R^{87}$, $R^{88}$ and $R^{89}$ each independently represents hydrogen, $C_{1-3}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl) and $R^{80}$ is as defined herein);

14) $C_{2-5}$alkenyl$X^{16}R^{80}$ (wherein $X^{16}$ represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{90}C(O)-$, $-C(O)NR^{91}-$, $-SO_2NR^{92}-$, $-NR^{93}SO_2-$ or $-NR^{94}-$ (wherein $R^{90}$, $R^{91}$, $R^{92}$, $R^{93}$ and $R^{94}$ each independently represents hydrogen, $C_{1-3}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl) and $R^{80}$ is as defined herein);

15) $C_{2-5}$alkynyl$X^{17}R^{80}$ (wherein $X^{17}$ represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{95}C(O)-$, $-C(O)NR^{96}-$, $-SO_2NR^{97}-$, $-NR^{98}SO_2-$ or $-NR^{99}-$ (wherein $R^{95}$, $R^{96}$, $R^{97}$, $R^{98}$ and $R^{99}$ each independently represents hydrogen, $C_{1-3}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl) and $R^{80}$ is as defined herein);

16) $C_{1-4}$alkyl$X^{18}C_{1-4}$alkyl$R^{80}$ (wherein $X^{18}$ represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{100}C(O)-$, $-C(O)NR^{101}-$, $-SO_2NR^{102}-$, $-NR^{103}SO_2-$ or $-NR^{104}-$ (wherein $R^{100}$, $R^{101}$, $R^{102}$, $R^{103}$ and $R^{104}$ each independently represents hydrogen, $C_{1-3}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl) and $R^{80}$ is as defined herein);

17) $C_{1-4}$alkyl$X^{18}C_{1-4}$alkyl$R^{79}$ (wherein $X^{18}$ and $R^{79}$ are as defined herein);

18) $C_{2-5}$alkenyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, $C_{1-4}$alkylamino, N,N-di($C_{1-4}$alkyl)amino, aminosulphonyl, N-$C_{1-4}$alkylaminosulphonyl and N,N-di($C_{1-4}$alkyl)aminosulphonyl;

19) $C_{2-5}$alkynyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, $C_{1-4}$alkylamino, N,N-di($C_{1-4}$alkyl)amino, aminosulphonyl, N-$C_{1-4}$alkylaminosulphonyl and N,N-di($C_{1-4}$alkyl)aminosulphonyl;

20) $C_{2-5}$alkenyl$X^{18}C_{1-4}$alkyl$R^{79}$ (wherein $X^{18}$ and $R^{79}$ are as defined herein);

21) $C_{2-5}$alkynyl$X^{18}C_{1-4}$alkyl$R^{79}$ (wherein $X^{18}$ and $R^{79}$ are as defined herein); and

22) $C_{1-4}$alkyl$R^{105}(C_{1-4}alkyl)_x(X^{18})_yR^{106}$ (wherein $X^{18}$ is as defined herein, x is 0 or 1, y is 0 or 1, and $R^{105}$ and $R^{106}$ are each independently selected from hydrogen, $C_{1-3}$alkyl, cyclopentyl, cyclohexyl and a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which $C_{1-3}$alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and $C_{1-4}$alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, $C_{1-4}$cyanoalkyl, $C_{1-4}$alkyl, $C_{1-4}$hydroxyalkyl, $C_{1-4}$alkoxy, $C_{1-4}$alkoxy$C_{1-4}$alkyl, $C_{1-4}$alkylsulphonyl$C_{1-4}$alkyl, $C_{1-4}$alkoxycarbonyl, $C_{1-4}$aminoalkyl, $C_{1-4}$alkylamino, di($C_{1-4}$alkyl)amino, $C_{1-4}$alkylamino$C_{1-4}$alkyl, di($C_{1-4}$alkyl)amino$C_{1-4}$alkyl, $C_{1-4}$alkylamino$C_{1-4}$alkoxy, di($C_{1-4}$alkyl)amino$C_{1-4}$alkoxy and a group -(-O-)$_f$($C_{1-4}$alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from $C_{1-4}$alkyl) with the proviso that $R^{105}$ cannot be hydrogen);

and additionally wherein any $C_{1-5}$alkyl, $C_{2-5}$alkenyl or $C_{2-5}$alkynyl group in $R^{56}X^{10}$- may bear one or more substituents selected from hydroxy, halogeno and amino;

$R^{2a}$ represents hydrogen, halogeno, $C_{1-3}$alkyl, trifluoromethyl, $C_{1-3}$alkoxy, $C_{1-3}$alkylsulphanyl, -$NR^{3a}R^{4a}$ (wherein $R^{3a}$ and $R^{4a}$, which may be the same or different, each represents hydrogen or $C_{1-3}$alkyl), or $R^{5a}(CH_2)_{za}X^{1a}$ (wherein $R^{5a}$ is a 4-, 5- or 6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno,

cyano, $C_{1-4}$cyanoalkyl, $C_{1-4}$alkyl, $C_{1-4}$hydroxyalkyl, $C_{1-4}$alkoxy, $C_{1-4}$alkoxy$C_{1-4}$alkyl, $C_{1-4}$alkylsulphonyl$C_{1-4}$alkyl, $C_{1-4}$alkoxycarbonyl, $C_{1-4}$aminoalkyl, $C_{1-4}$alkylamino, di($C_{1-4}$alkyl)amino, $C_{1-4}$alkylamino$C_{1-4}$alkyl, di($C_{1-4}$alkyl)amino$C_{1-4}$alkyl, $C_{1-4}$alkylamino$C_{1-4}$alkoxy, di($C_{1-4}$alkyl)amino$C_{1-4}$alkoxy and a group -(-O-)$_f$($C_{1-4}$alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from $C_{1-4}$alkyl), za is an integer from 0 to 4 and $X^{1a}$ represents a direct bond, -O-, -$CH_2$-, -S-, -SO-, -$SO_2$-, -$NR^{6a}$C(O)-, -C(O)$NR^{7a}$-, -$SO_2NR^{8a}$-, -$NR^{9a}SO_2$- or -$NR^{10a}$- (wherein $R^{6a}$, $R^{7a}$, $R^{8a}$, $R^{9a}$ and $R^{10a}$ each independently represents hydrogen, $C_{1-3}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl));

or a salt ~~or prodrug~~ thereof,

with the proviso that $R^2$ is not hydrogen.

Claim 40 (**previously presented**): A compound of the formula II according to claim 39 wherein $R^2$ represents hydroxy, halogeno, cyano, nitro, trifluoromethyl, $C_{1-3}$alkyl, amino or $R^5X^1$-, wherein $X^1$ is as defined in claim 39 and $R^5$ is selected from one of the following twenty-two groups:

1) $C_{1-4}$alkyl which may be unsubstituted or which may be substituted with one or more groups selected from fluoro, chloro and bromo, or $C_{2-5}$alkyl which may be unsubstituted or substituted with one or more groups selected from hydroxy and amino;
2) $C_{2-3}$alkyl$X^2$C(O)$R^{11}$ (wherein $X^2$ is as defined in claim 39 and $R^{11}$ represents -$NR^{13}R^{14}$ or -$OR^{15}$ (wherein $R^{13}$, $R^{14}$ and $R^{15}$ which may be the same or different are each $C_{1-4}$alkyl or $C_{1-2}$alkoxyethyl));
3) $C_{2-4}$alkyl$X^3R^{16}$ (wherein $X^3$ is as defined in claim 39 and $R^{16}$ is a group selected from $C_{1-3}$alkyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl and tetrahydropyranyl, which $C_{1-3}$alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and $C_{1-2}$alkoxy and which cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl or tetrahydropyranyl group may bear 1 or 2 substituents selected from oxo,

hydroxy, halogeno, cyano, $C_{1-3}$cyanoalkyl, $C_{1-3}$alkyl, $C_{1-3}$hydroxyalkyl, $C_{1-3}$alkoxy, $C_{1-2}$alkoxy$C_{1-3}$alkyl, $C_{1-2}$alkylsulphonyl$C_{1-3}$alkyl, $C_{1-3}$alkoxycarbonyl, $C_{1-3}$alkylamino, di($C_{1-3}$alkyl)amino, $C_{1-3}$alkylamino$C_{1-3}$alkyl, di($C_{1-3}$alkyl)amino$C_{1-3}$alkyl, $C_{1-3}$alkylamino$C_{1-3}$alkoxy, di($C_{1-3}$alkyl)amino$C_{1-3}$alkoxy and a group -(-O-)$_f$($C_{1-3}$alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a heterocyclic group selected from pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl, morpholino and thiomorpholino, which cyclic group may bear one or more substituents selected from $C_{1-3}$alkyl));

4) $C_{2-3}$alkyl$X^4C_{2-3}$alkyl$X^5R^{22}$ (wherein $X^4$ and $X^5$ are as defined in claim 39 and $R^{22}$ represents hydrogen or $C_{1-3}$alkyl);

5) $R^{28}$ (wherein $R^{28}$ is as defined in claim 39);

6) $C_{1-4}$alkyl$R^{110}$ (wherein $R^{110}$ is a group selected from pyrrolidinyl, piperazinyl, piperidinyl, imidazolidin-1-yl, azetidinyl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl and 1,3-dithian-2-yl, which group is linked to $C_{1-4}$alkyl through a carbon atom and which group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, $C_{1-3}$cyanoalkyl, $C_{1-3}$alkyl, $C_{1-3}$hydroxyalkyl, $C_{1-3}$alkoxy, $C_{1-2}$alkoxy$C_{1-3}$alkyl, $C_{1-2}$alkylsulphonyl$C_{1-3}$alkyl, $C_{1-3}$alkoxycarbonyl, $C_{1-3}$alkylamino, di($C_{1-3}$alkyl)amino, $C_{1-3}$alkylamino$C_{1-3}$alkyl, di($C_{1-3}$alkyl)amino$C_{1-3}$alkyl, $C_{1-3}$alkylamino$C_{1-3}$alkoxy, di($C_{1-3}$alkyl)amino$C_{1-3}$alkoxy and a group -(-O-)$_f$($C_{1-3}$alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a heterocyclic group selected from pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl, morpholino and thiomorpholino, which cyclic group may bear one or more substituents selected from $C_{1-3}$alkyl)) or $C_{2-4}$alkyl$R^{111}$ (wherein $R^{111}$ is a group selected from morpholino, thiomorpholino, azetidin-1-yl, pyrrolidin-1-yl, piperazin-1-yl and piperidino which group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, $C_{1-3}$cyanoalkyl, $C_{1-3}$alkyl, $C_{1-3}$hydroxyalkyl, $C_{1-3}$alkoxy, $C_{1-2}$alkoxy$C_{1-3}$alkyl, $C_{1-2}$alkylsulphonyl$C_{1-3}$alkyl, $C_{1-3}$alkoxycarbonyl, $C_{1-3}$alkylamino, di($C_{1-3}$alkyl)amino, $C_{1-3}$alkylamino$C_{1-3}$alkyl, di($C_{1-3}$alkyl)amino$C_{1-3}$alkyl, $C_{1-3}$alkylamino$C_{1-3}$alkoxy, di($C_{1-3}$alkyl)amino$C_{1-3}$alkoxy and a group

-(-O-)$_f$($C_{1-3}$alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a heterocyclic group selected from pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl, morpholino and thiomorpholino, which cyclic group may bear one or more substituents selected from $C_{1-3}$alkyl));

7) $C_{3-4}$alkenyl$R^{112}$ (wherein $R^{112}$ represents $R^{110}$ or $R^{111}$ as defined herein);

8) $C_{3-4}$alkynyl$R^{112}$ (wherein $R^{112}$ represents $R^{110}$ or $R^{111}$ as defined herein);

9) $R^{29}$ (wherein $R^{29}$ is as defined in claim 39);

10) $C_{1-4}$alkyl$R^{29}$ (wherein $R^{29}$ is as defined in claim 39);

11) 1-$R^{29}$prop-1-en-3-yl or 1-$R^{29}$but-2-en-4-yl (wherein $R^{29}$ is as defined in claim 39 with the proviso that when $R^5$ is 1-$R^{29}$prop-1-en-3-yl, $R^{29}$ is linked to the alkenyl group via a carbon atom);

12) 1-$R^{29}$prop-1-yn-3-yl or 1-$R^{29}$but-2-yn-4-yl (wherein $R^{29}$ is as defined in claim 39 with the proviso that when $R^5$ is 1-$R^{29}$prop-1-yn-3-yl, $R^{29}$ is linked to the alkynyl group via a carbon atom);

13) $C_{1-5}$alkyl$X^6R^{29}$ (wherein $X^6$ and $R^{29}$ are as defined in claim 39);

14) 1-($R^{29}X^7$)but-2-en-4-yl (wherein $X^7$ and $R^{29}$ are as defined in claim 39);

15) 1-($R^{29}X^8$)but-2-yn-4-yl (wherein $X^8$ and $R^{29}$ are as defined in claim 39);

16) $C_{2-3}$alkyl$X^9C_{1-3}$alkyl$R^{29}$ (wherein $X^9$ and $R^{29}$ are as defined in claim 39);

17) $C_{2-3}$alkyl$X^9C_{1-3}$alkyl$R^{28}$ (wherein $X^9$ and $R^{28}$ are as defined in claim 39);

18) $C_{2-5}$alkenyl which may be unsubstituted or which may be substituted with one or more fluorine atoms or with one or two groups selected from hydroxy, fluoro, amino, $C_{1-4}$alkylamino, N,N-di($C_{1-4}$alkyl)amino, aminosulphonyl, N-$C_{1-4}$alkylaminosulphonyl and N,N-di($C_{1-4}$alkyl)aminosulphonyl;

19) $C_{2-5}$alkynyl which may be unsubstituted or which may be substituted with one or more fluorine atoms or with one or two groups selected from hydroxy, fluoro, amino, $C_{1-4}$alkylamino, N,N-di($C_{1-4}$alkyl)amino, aminosulphonyl, N-$C_{1-4}$alkylaminosulphonyl and N,N-di($C_{1-4}$alkyl)aminosulphonyl;

20) $C_{2-4}$alkenyl$X^9C_{1-3}$alkyl$R^{28}$ (wherein $X^9$ and $R^{28}$ are as defined in claim 39);

21) $C_{2-4}$alkynyl$X^9C_{1-3}$alkyl$R^{28}$ (wherein $X^9$ and $R^{28}$ are as defined in claim 39); and

22) $C_{1-3}$alkyl$R^{54}$($C_{1-3}$alkyl)$_q$($X^9$)$_r$$R^{55}$ (wherein $X^9$, q, r, $R^{54}$ and $R^{55}$ are as defined in claim 39);

and additionally wherein any $C_{1-5}$alkyl, $C_{2-5}$alkenyl or $C_{2-5}$alkynyl group in $R^5X^1$- may bear one or more substituents selected from hydroxy, halogeno and amino.

Claim 41 (**previously presented**): A compound according to claim 39 wherein Zb is -O-.

Claim 42 (**cancelled**).

Claim 43 (**previously presented**): A compound according to claim 39 wherein $R^1$ represents oxo, halogeno, hydroxy, $C_{1-2}$alkoxy, $C_{1-2}$alkyl, $C_{1-2}$alkoxymethyl, $C_{2-3}$alkanoyl, $C_{1-2}$haloalkyl, cyano, amino, $C_{2-4}$alkenyl, $C_{2-4}$alkynyl, $C_{2-3}$alkanoyloxy, nitro, $C_{2-3}$alkanoylamino, $C_{1-2}$alkoxycarbonyl, $C_{1-2}$alkylsulphanyl, $C_{1-2}$alkylsulphinyl, $C_{1-2}$alkylsulphonyl, carbamoyl, N-$C_{1-2}$alkylcarbamoyl, N,N-di($C_{1-2}$alkyl)carbamoyl, aminosulphonyl, N-$C_{1-2}$alkylaminosulphonyl, N,N-di($C_{1-2}$alkyl)aminosulphonyl, N-($C_{1-2}$alkylsulphonyl)amino, N-($C_{1-2}$alkylsulphonyl)-N-($C_{1-2}$alkyl)amino or a $C_{3-7}$alkylene chain joined to two ring C carbon atoms.

Claim 44 (**previously presented**): A compound according to claim 39 wherein n is 0, 1 or 2.

Claim 45 (**presently amended**): A compound according to claim 39 wherein Zb is -O-, with the proviso that $R^2$ is not ~~hydrogen,~~ substituted or unsubstituted $C_{1-5}$alkyl, halogeno, $C_{1-5}$alkoxy, $C_{2-5}$alkenyl, phenoxy or phenyl$C_{1-5}$alkoxy.

Claim 46 (**previously presented**): A compound according to claim 39 selected from 6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)-4-(quinolin-7-yloxy)quinazoline, 7-(3-(1,1-dioxothiomorpholino)propoxy)-6-methoxy-4-(quinolin-7-yloxy)quinazoline,

6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)-4-(quinolin-7-yloxy)quinazoline,

6-methoxy-7-((1-methylpiperidin-3-yl)methoxy)-4-(quinolin-7-yloxy)quinazoline,

4-(4-chloroquinolin-7-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)-4-(4-methylquinolin-7-yloxy) quinazoline,

6-methoxy-4-(4-methylquinolin-7-yloxy)-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,

6-methoxy-7-(2-(2-methoxyethoxy)ethoxy)-4-(quinolin-7-yloxy)quinazoline,

6-methoxy-7-((1-(2-methylsulphonylethyl)piperidin-4-yl)methoxy)-4-(quinolin-7-yloxy)quin azoline,

4-(2,3-dimethylindol-5-yloxy)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy) quinazoline,

4-(2,3-dimethylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline,

6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)-4-(2-trifluoromethylindol-5-yloxy) quinazoline,

6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline,

(*R*,*S*)-4-(3-fluoroquinolin-7-yloxy)-6-methoxy-7-((1-methylpiperidin-3-yl)methoxy) quinazoline,

4-(indol-5-yloxy)-6-methoxy-7-(3-methylsulphonylpropoxy)quinazoline,

7-(3-N,N-dimethylaminopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(2-morpholinoethoxy)ethoxy)quinazoline,

7-(2-(N,N-diethylamino)ethoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,

6-methoxy-7-(3-piperidinopropoxy)-4-(quinolin-7-yloxy)quinazoline,

4-(2-methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline,

4-(2-methylindol-5-yloxy)-7-(2-(piperidin-1-yl)ethoxy)quinazoline,

4-(2-methylindol-5-yloxy)-7-(2-(1*H*-1,2,4-triazol-1-yl)ethoxy)quinazoline,

6-methoxy-7-(3-piperidinopropoxy)-4-(6-trifluoromethylindol-5-yloxy)quinazoline,

7-(3-(methylsulphonyl)propoxy)-4-(2-methylindol-5-yloxy)quinazoline,

7-(3-(N,N-dimethylamino)propoxy)-4-(2,3-dimethylindol-5-yloxy)-6-methoxy-quinazoline,

4-(2,3-dimethylindol-5-yloxy)-6-methoxy-7-(1-methylpiperidin-3-ylmethoxy) quinazoline,

7-(2-(N,N-diethylamino)ethoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,

4-(indol-5-yloxy)-6-methoxy-7-(2-(piperidin-2-yl)ethoxy)quinazoline,

4-(indol-5-yloxy)-6-methoxy-7-(2-(piperidin-1-yl)ethoxy)quinazoline,
4-(indol-6-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
7-(3-(ethylsulphonyl)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,
6-methoxy-4-(3-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline,
7-(2-hydroxy-3-piperidinopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,
7-(2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(N-methylamino)ethoxy)quinazoline, and
7-(2-hydroxy-3-(isopropylamino)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,
or a salt thereof.

Claim 47 (**previously presented**): A compound according to claim 39 selected from
6-methoxy-7-(3-morpholinopropoxy)-4-(quinolin-7-yloxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-((1-methylpiperidin-4-yl)methoxy)quinazoline,
4-(indol-5-yloxy)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
4-(indol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-(3-methylsulphonylpropoxy)quinazoline,
7-((1-cyanomethyl)piperidin-4-ylmethoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-morpholinoethoxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-pyrrolidin-1-ylethoxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-(1-methylpiperidin-3-ylmethoxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-piperidinoethoxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(N-methyl-N-(4-pyridyl)amino)ethoxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline,
6-methoxy-7-(2-(2-methoxyethoxy)ethoxy)-4-(2-methylindol-5-yloxy)quinazoline,
6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(1*H*-1,2,4-triazol-1-yl)ethoxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(2-(4-methylpiperazin-1-yl)ethoxy)ethoxy) quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline,

4-(indol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,

6-methoxy-7-(1-(2-methoxyethyl)piperidin-4-ylmethoxy)-4-(2-methylindol-5-yloxy) quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-((2-(2-pyrrolidin-1-ylethyl)carbamoyl)vinyl) quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(3-(4-methypiperazin-1-yl)propoxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(piperidin-4-yloxy)ethoxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(N-methyl-N-methylsulphonylamino)ethoxy)qui nazoline,

7-(2-(1-(2-cyanoethyl)piperidin-4-yloxy)ethoxy)-6-methoxy-4-(2-methylindol-5-yloxy) quinazoline,

4-(2-methylindol-5-yloxy)-7-(3-(pyrrolidin-yl)propoxy)quinazoline,

4-(2-methylindol-5-yloxy)-7-(3-(1,1-dioxothiomorpholino)propoxy)quinazoline,

4-(2-methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline,

4-(indol-5-yloxy)-6-methoxy-7-(2-(2-methoxyethoxy)ethoxy)quinazoline,

7-(3-(N,N-dimethylamino)propoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,

7-(3-(N,N-diethylamino)propoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,

7-(3-(1,1-dioxothiomorpholino)propoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,

4-(indol-5-yloxy)-6-methoxy-7-(2-(4-pyridyloxy)ethoxy)quinazoline,

4-(indol-6-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,

7-(1-(2-methoxyethyl)piperidin-4-ylmethoxy)-4-(2-methylindol-5-yloxy)quinazoline,

7-(2-hydroxy-3-morpholinopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,

7-(2-(1-(2-methoxyethyl)piperidin-4-yl)ethoxy)-6-methoxy-4-(2-methylindol-5-yloxy) quinazoline,

7-(2-hydroxy-3-pyrrolidin-1-ylpropoxy)-6-methoxy-4-(2-methylindol-5-yloxy) quinazoline,

7-(3-(N,N-diethylamino)-2-hydroxypropoxy)-6-methoxy-4-(2-methylindol-5-yloxy) quinazoline,

7-(3-(1,1-dioxothiomorpholino)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy) quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(4-pyridyloxy)ethoxy)quinazoline,

4-(indol-5-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

(2*R*)-6-methoxy-(2-methyl-1*H*-indol-5-yloxy)-7-(2-hydroxy-3-piperidinopropoxy) quinazoline,

(5*R*)-6-methoxy-4-(2-methyl-1*H*-indol-5-yloxy)-7-(2-oxopyrrolidin-5-ylmethoxy) quinazoline,

4-(4-bromoindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(1-(2-(pyrrolidin-1-yl)ethyl)-piperidin-4-ylmethoxy)quinazoline,

(2*R*)-7-(2-hydroxy-3-(pyrrolidin-1-yl)propoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,

(2*R*)-7-(2-hydroxy-3-morpholinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,

(2*R*)-7-(2-hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,

(2*S*)-7-(2-hydroxy-3-((N,N-diisopropyl)amino)propoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,

(2*S*)-7-(2-hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,

(2*R*)-7-(2-hydroxy-3-piperidinopropoxy)-6-methoxy-4-(3-methylindol-5-yloxy) quinazoline,

(2*R*)-7-(2-hydroxy-3-(pyrrolidin-1-yl)propoxy)-6-methoxy-4-(3-methylindol-5-yloxy) quinazoline,

(2*R*)-7-(2-hydroxy-3-(pyrrolidin-1-yl)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,

(2*R*)-7-(2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy)6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(1-(2-morpholinoethyl)piperidin-4-ylmethoxy) quinazoline,

4-(3-fluoro-quinolin-7-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,

4-(3-fluoro-quinolin-7-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,

6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)-4-(1*H*-pyrrolo[2,3-*b*]pyridin-5-yloxy) quinazoline,
(2*S*)-6-methoxy-(2-methyl-1*H*-indol-5-yloxy)-7-(2-hydroxy-3-piperidinopropoxy) quinazoline, and
4-(6-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy) quinazoline,
or a salt thereof.

Claim 48 (**previously presented**): A compound according to claim 39 selected from 6-methoxy-4-(2-methylindol-5-yloxy)-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,
4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazoline,
4-(6-fluoroindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy) quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy) quinazoline,
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy) quinazoline,
4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(2-(1-methylpiperidin-4-yl)ethoxy)quinazoline,
(2*R*)-7-(2-hydroxy-3-(pyrrolidin-1-yl)propoxy)-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline, and
4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(2-(1-methylpiperidin-4-yl)ethoxy) quinazoline,
or a salt thereof.

Claim 49 (**previously presented**): A compound according to claim 39 in the form of a pharmaceutically acceptable salt.

Claim 50 **(cancelled)**.

Claims 51 (**currently amended**): A pharmaceutical composition which comprises as active ingredient a compound of formula II~~-I~~ or a pharmaceutically acceptable salt thereof according to any one of claims 39-41, 43-48 and 61~~-claim 39~~ in association with a pharmaceutically acceptable excipient or carrier.

Claims 52-60 **(cancelled)**.

Claim 61 (**previously presented**): A compound according to claim 39 wherein ring C is selected from indolyl and quinolinyl.

Claim 62 **(cancelled).**

Claim 63 (**new**): A method for inhibiting VEGF receptor tyrosine kinase activity in a warm-blooded animal in need thereof comprising administering to said animal an inhibiting amount of a compound of the formula II as defined in any one of claims 39-41, 43-48 and 61 or a pharmaceutically acceptable salt thereof.